SCHEMBL4551241

SCHEMBL4551241

CCN1C(=O)N(c2c(F)ccc(O)c2F)Cc2cnc(NC3CCC(N)CC3)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.40
FGFR1 P11362 1/20 0.37
MAPK8 P45983 3/20 0.37
MAPK10 P53779 3/20 0.37
CDK4 P11802 2/20 0.36
CCND1 P24385 2/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
CDK7 P50613 2/20 0.36
CDK9 P50750 2/20 0.36
CCNK O75909 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CDK13 Q14004 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
TNK2 Q07912 2/20 0.36
MAP4K2 Q12851 2/20 0.36
CDK1 P06493 2/20 0.35
CDK2 P24941 1/20 0.35
MAPK14 Q16539 3/20 0.34
MAPK9 P45984 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4398463 0.92 MAPK14 (0.42) FGFR4FGFR1MAPK8MAPK10CDK4
SCHEMBL4406449 0.90 FGFR4 (0.39) FGFR4FGFR1CDK4CCND1CCND2
SCHEMBL4406742 0.89 FGFR4 (0.42) FGFR4FGFR1MAPK8MAPK10CDK4
SCHEMBL4398701 0.89 FGFR4 (0.47) FGFR4FGFR1CDK4CCND1CDK7
SCHEMBL4412475 0.87 TNK2 (0.39) FGFR4FGFR1MAPK8MAPK10CDK4
SCHEMBL4404443 0.86 FGFR4 (0.41) FGFR4FGFR1MAPK8MAPK10TNK2
SCHEMBL4404744 0.85 FGFR4 (0.46) FGFR4FGFR1
SCHEMBL4407910 0.85 FGFR4 (0.53) FGFR4FGFR1
SCHEMBL4411308 0.85 FGFR4 (0.41) FGFR4FGFR1MAPK14
SCHEMBL4398885 0.85 FGFR4 (0.42) FGFR4FGFR1MAPK8MAPK10TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 FGFR4 191/4885FGFR1 88/4885MAPK8 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.